Immunotherapy antibodies: a treatment for melanoma, and the next blockbuster?

As someone who is quite engaged with the antibody space, it always surprises me when therapeutic antibody developments hit mainstream news. The bulk of the research into therapeutic antibodies, ADCs, bispecifics and the like is often buried deep in the pages of scientific journals or pharmaceutical news websites, so I certainly found it surprising when a colleague of mine asked me …

project data sphere

Why you should share your clinical and patient records data

  Many pharmaceutical companies are now seeing the benefits of sharing clinical trial or patient data to create a pool of data where so far unidentified patterns might emerge. These practices require the standardisation of electronic records, and can be challenged by patient privacy concerns, but they can help us develop better treatments for diseases. As Michael Keiser, instructor at …

BioPharma Mexico is where experts like AstraZeneca's Ajam Gautam meet to network, learn from each other, and discuss the latest biopharma strategies and technology.

AstraZeneca’s Ajay Gautam on Innovative R&D for Emerging Markets

We were glad to have Ajay Gautam, Executive Director and Head of Emerging Markets R&D at AstraZeneca, present at last year’s BioPharma Mexico. You can now download his slides from the event, where he addressed innovative R&D models for emerging markets under the main heading “How to grow the Mexican pharma industry”. View the presentation here Dr. Gautam has a …

Pharma M&A Biomedical in the north

The Northern Factor and Scientific Research

Whilst the news has been dominated by Pfizer and AstraZeneca, there has been a very different story developing in the north of the UK. The Northern Health Science Alliance (NHSA) has brought together eight universities, eight NHS trusts and announced links with foreign companies, from the US and Sweden to develop new products and create ‘an internationally recognized life science …

Stem Cells Live: We Are Not BigPharma and Why We Need to Change the Game

The pharma game needs to change. Big Pharma shaped the way drugs are developed, regulated, manufactured, and brought to market. This needs to change. As the biotech scene becomes more and more specialised (whether in regenerative medicine, orphan indications etc.) the current pharmaceutical framework only constrains the industry further. This is the message that rings out from World Stem Cells …

Live Long & Prosper? A New Report Highlights Economic & Health Benefits of A Growing Regenerative Medicine Sector

London, United Kingdom, May 22, 2014 Aging Analytics & The London Regenerative Medicine Network have co-published ‘Investing in Regenerative Medicine: Technology Analysis & Market Outlook’, a 106 page primer on Regenerative Medicine sector. Freely available and designed to inform industry stakeholders from investors and corporations through to government departments and the general public, the report highlights the significant potential for …

Download: Organisational models for R&D

At last year’s Exploratory Clinical Development World Europe event, Johan Luthman from Merck Research Laboratories, gave a presentation entitled “Organisational models for R&D” In his presentation he discusses how the pharmaceutical industry is changing and takes a look at key models and processes that need to be understood in order to move with the changing industry. He quotes Alan Wilson …